In this video, Bruno Paiva, PhD, University of Navarra, Pamplona, Spain, discusses the clinical significance of measurable residual disease (MRD) in light-chain (AL) amyloidosis. Dr Paiva notes that a multicenter international European study involving 320 patients with AL amyloidosis demonstrated the prognostic value of MRD but, unfortunately, found no association between MRD status and organ response. This interview took place at the 66th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
The clinical significance of MRD in AL amyloidosis
Теги
Speaker: Bruno PaivaInstitution: University of NavarraEvent: ASH 2024Format: InterviewSubject: AmyloidosisSubject: Rare DiseasesField: MRDField: TransplantationField: TreatmentField: Immuno-oncologyField: DiagnosisMedicines: AntibodiesMedicines: BortezomibMedicines: Daratumumaborgan responsehematologic CRcardiac involvementprognosisprognostic valuemeasurable residual diseaseAL amyloidosis
